HONG KONG, Sept. 29, 2026 /PRNewswire/ -- City University of Hong Kong (CityUHK) has achieved its best-ever results in the newly released Times Higher Education (THE) World University Rankings 2027, advancing three places to rank 70th globally.
CityUHK demonstrated stellar performance across multiple evaluation metrics, notably retaining the world No. 1 spot in the "Industry" pillar for the fourth consecutive year and remaining 1st in Hong Kong in "International Outlook". These achievements reaffirm the University's world-class strengths in pioneering research, international collaboration and knowledge transfer. CityUHK also recorded across-the-board score improvements in the three core pillars of Teaching, Research Environment and Research Quality.
The THE World University Rankings 2027 evaluated 2,297 institutions across 118 countries and territories using 17 indicators grouped under five core pillars: Teaching, Research Environment, Research Quality, Industry and International Outlook. Mr Phil Baty, Chief Global Affairs Officer at THE, pointed out that the latest results reflect a permanent shift in the tectonic plates of global higher education, signalling a historic realignment of academic power from West to East and remaking the geography of academic excellence. In its official press release, THE also highlighted that the overall performance of Hong Kong's higher education institutions continues to be strong, specifically noting that CityUHK has achieved its highest position to date.
"At a time of intensifying global competition, it is remarkable that CityUHK has continued its strong progress in the world university rankings, now moving into the world top 70 group," said Mr Baty. "Universities need to have real strength-in-depth across our 17 metrics to perform so well in the rankings, but CityUHK has particular strength in its international outlook, which is a fantastic signal of being a global magnet for talent and partnerships and it has the highest score in the world, jointly, for its outstanding industry collaboration and technology transfer. These strengths combine to create a very potent force for good. Congratulations to all at a highly successful global research university."
In industry-academia-research collaboration and internationalisation, CityUHK scored a perfect 100 in the "Industry" pillar, ranking 1st in the world for the fourth consecutive year. This accolade underscores the University's pre-eminent standing in patent development, technology commercialisation, and the promotion of a dynamic innovation and entrepreneurship ecosystem.
Furthermore, having been named the "Most International University in the World" by THE for three consecutive years, CityUHK retained the top position in Hong Kong in "International Outlook" for the ninth consecutive year.
CityUHK also achieved continuous breakthroughs in academic reputation and research excellence. Scores for "Teaching Reputation" and "Research Reputation" climbed for the second consecutive year, while the "Research Quality" pillar surged into the global top 50, bolstered by full marks across multiple critical indicators.
"CityUHK has seen robust development in recent years, with its academic achievements and innovative research highly recognised both locally and internationally. The University has firmly established itself among the top 100 worldwide in four major global university rankings, which serves as a resounding affirmation of the CityUHK community's steadfast commitment to innovation and research excellence," said Professor Chun-Sing Lee, Acting President of CityUHK. "CityUHK will continue to embrace a pioneering mindset, deepen international research and pedagogical collaboration, and address pressing global challenges through visionary research outcomes and deep-seated industry-academia-research synergy."
He added, "We remain dedicated to nurturing future leaders equipped with global competitiveness and social responsibility, continuously contributing to developing Hong Kong as an international post-secondary education hub and a cradle of world-class talent."
CityUHK's academic excellence has been consistently validated across major international benchmarks. In the QS World University Rankings 2027, CityUHK rose 11 places to 52nd globally, placing it firmly within the top 3% of universities worldwide. In the U.S. News & World Report 2026–2027 Best Global Universities Rankings, CityUHK climbed seven spots to 47th globally. And in the ShanghaiRanking Academic Ranking of World Universities 2026, CityUHK maintained its position among the world's top 100 for the second consecutive year, ranking 95th globally and 2nd in Hong Kong. These accolades demonstrate the University's continuously rising academic reputation and influence within the global higher education landscape.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CityUHK achieves historic high in THE World University Rankings 2027, soaring to 70th globally
- Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure.
- With its investment through the Life Sciences Scale-Up Fund, the Ontario government is supporting healthcare innovation and reinforcing its province's leadership position in the life sciences.
- This project will create 12 new jobs and protect 183 existing positions, unlocking new market opportunities and strengthening the sector's competitiveness.
MUMBAI, India, Sept. 30, 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), today announced that its Aurora, Canada drug substance site has received a $1,753,620 investment from the Ontario government through the Life Sciences Scale-Up Fund (LSSUF), enabling PPS to upgrade site infrastructure and commercialize Ontario-made health technologies for new markets.
With support from the government of Ontario, Piramal Pharma is investing $5,314,000 to upgrade site infrastructure at their Aurora facility, strengthening Ontario's pharmaceutical manufacturing and bolstering domestic production of APIs. This project will enhance R&D and clinical API production, ensure the commercial availability of critical drug substances, and support a resilient and globally competitive life sciences industry in Ontario. The investment will create 12 new jobs and protect 183 existing positions.
"We are grateful to the Government of Ontario and MPP Dawn Gallagher Murphy for their support of this important investment in our Aurora facility," said Peter DeYoung, CEO, Piramal Global Pharma. "This funding will help enable Piramal Pharma Solutions to upgrade our site infrastructure, strengthen our manufacturing capabilities, and enhance our ability to serve patients and customers around the world. In addition to supporting business growth, this investment will help advance projects focused on sustainability, operational efficiency, and the modernization of our site, reinforcing our commitment to responsible manufacturing and environmental stewardship."
"Through the Life Sciences Scale-Up Fund, our government is ensuring that Ontario businesses are positioned to develop, commercialize and deploy new technologies across the health-care system," said Dawn Gallagher Murphy, Member of Provincial Parliament for Newmarket—Aurora. "With this investment, Piramal will be positioned to turn their latest ideas into market-ready solutions, all while creating good-paying jobs and reinforcing Ontario's position as a global biomanufacturing and life sciences hub."
First launched in 2024, the $24 million LSSUF works in tandem with the government's Health Innovation Pathway to advance the objectives of Phase 2 of Ontario's Life Sciences Strategy and strengthen Ontario's position as a global leader in health innovation. Building on the fund's initial success, the 2026 Ontario Budget invested an additional $24 million to support Ontario companies whose work will accelerate the adoption of innovative technologies in the health-care system and support the province's broader vision of providing connected, convenient care closer to home.
"Ontario's life sciences sector plays a critical role in supporting the discovery and development of innovative medicines and technologies, which is why our government is proud to support local companies as they take their Ontario-made products to the next level," said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. "By investing in Piramal through the Life Sciences Scale-Up Fund, we are scaling up our province's domestic capacity while further positioning Ontario as a leading jurisdiction for life sciences investment for generations to come."
By investing in the Aurora site, the Ontario government is strengthening Ontario's leadership in the life sciences and helping PPS advance next-generation technologies to patients worldwide.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited.
For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X
About Piramal Pharma Limited
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.
For more information, visit: Piramal Pharma | LinkedIn
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
